Blog

Running a successful clinical trial requires precision, compliance, and above all—integrity of your data. One of the greatest threats to this integrity? Professional research subjects and duplicate subjects in clinical trials. Many sponsors and CROs underestimate the frequency and impact of dual enrollment in clinical trials. Yet, it’s not a matter of if it will

Introduction In today’s fast-paced clinical research environment, ensuring data integrity and participant safety has never been more critical. One of the most persistent threats to these core objectives is the issue of duplicate research subjects in clinical trials—individuals who enroll in multiple studies concurrently or in close succession, often without disclosing prior participation. Verified Clinical

Clinical trials for GLP-1 receptor agonists and obesity clinical trials face unique challenges due to the high level of interest from participants who are eager to lose weight or manage metabolic disorders. One major concern is duplicate enrollment in clinical trials, where subjects attempt to participate in multiple studies simultaneously. This can happen for several

Clinical trials are the backbone of medical advancements, providing the data necessary to develop new treatments and therapies. However, one of the biggest challenges facing the research community is ensuring data integrity and participant safety. Duplicate subjects in clinical trials, fraudulent participation, and non-compliance can compromise results and endanger both subjects and the broader public.

The integrity of clinical trials is paramount to ensuring reliable results, patient safety, and regulatory compliance. However, duplicate subjects in clinical trials—individuals who enroll in multiple studies simultaneously or in rapid succession—pose a significant risk to data accuracy and patient safety. The issue is not confined to specific regions such as Florida or California or